deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
(Nasdaq:DCGN) today announced that its CLIA-registered DNA isolation and
genotyping laboratory, which processes the company’s deCODEme(TM) personal
genome scans and risk assessment diagnostic tests for several common
diseases, has been accredited by the American College of Pathologists (CAP)
following a recent inspection. The U.S. Centers for Medicare and Medicaid
Services (CMS) has granted the CAP Laboratory Accreditation Program deeming
authority, and its accreditations can also be used to meet many state
certification requirements.
“We believe that testing for genetic risk factors for common diseases is
going to play a central role in refocusing our healthcare system on
prevention and early intervention. deCODE has led the way in discovering
validated genetic risk factors for diseases with a major impact on public
health, and in bringing to market products that put this knowledge in the
hands of individuals and their doctors. Quality – in our world-leading
science and in-house genotyping and data analysis – sets us apart from our
competition in the field of personal genomics. CAP certification serves to
emphasize this advantage and will enable us to provide our products to an
ever wider public,” said
The CAP Laboratory Accreditation Program, begun in the 1960s, is an
internationally recognized program for certifying laboratory quality based
upon inspections conducted by practicing laboratory professionals. CAP
inspectors examine a laboratory’s records and quality control of precedures
for the preceding two years; the qualifications of all staff; equipment and
facilities; safety program and record; and overall management. The
inspections program is designed to ensure the highest standard of care for
all laboratory patients.
About the College of American Pathologists
The College of American Pathologists (CAP) is a medical society that
serves more than 17,000 physician members and the laboratory community
throughout the world. It is the world’s largest association composed
exclusively of pathologists and is widely considered the leader in laboratory
quality assurance. The CAP is an advocate for high quality and cost effective
medical care.
About deCODE
deCODE is a bio-pharmaceutical company developing drugs and DNA-based
tests to improve the treatment, diagnosis and prevention of common diseases.
Its lead therapeutic programs, which leverage the company’s expertise in
chemistry and structural biology, include DG041, an antiplatelet compound
being developed for the prevention of arterial thrombosis; DG051 and DG031,
compounds targeting the leukotriene pathway for the prevention of heart
attack; and DG071 and a platform for other PDE4 modulators with therapeutic
applications in Alzheimer’s disease and other conditions. deCODE is a global
leader in human genetics, and has identified key variations in the genome
(SNPs) conferring increased risk of major public health challenges from
cardiovascular disease to cancer. Based upon these discoveries deCODE has
brought to market a growing range of DNA-based tests for gauging risk and
empowering prevention of common diseases. Through its CLIA-registered
laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM)
for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE
ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type
of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer.
deCODE is delivering on the promise of the new genetics.SM Visit us on the
web at http://www.decode.com; on our diagnostics site at
http://www.decodediagnostics.com; for our pioneering personal genome analysis
service and new focused disease scans, integrating the genetic variants
included in these tests and those linked to another twenty common diseases,
as well as for our new deCODEme Cardio(TM) and deCODEme Cancer(TM) scans, at
http://www.decodeme.com; and on our blog at http://www.decodeyou.com.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and uncertainties
that could cause actual results, and the timing of events, to differ
materially from those described in the forward-looking statements. These
risks and uncertainties include, among others, those relating to our ability
to obtain sufficient financing to continue as a going concern, the outcome of
the review of the continued listing of our common stock on The Nasdaq Stock
Market, our ability to develop and market diagnostic products, the level of
third party reimbursement for our products, risks related to preclinical and
clinical development of pharmaceutical products, including the identification
of compounds and the completion of clinical trials, our ability to form
collaborative relationships, the effect of government regulation and the
regulatory approval processes, market acceptance, our ability to obtain and
protect intellectual property rights for our products, dependence on
collaborative relationships, the effect of competitive products, industry
trends and other risks identified in deCODE’s filings with the Securities and
Exchange Commission, including, without limitation, the risk factors
identified in our most recent Annual Report on Form 10-K and any updates to
those risk factors filed from time to time in our Quarterly Reports on Form
10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to
update or alter these forward-looking statements as a result of new
information, future events or otherwise.
Contacts:
deCODE genetics
Edward Farmer
+44-7796-010107
edward.farmer@decode.is
Gisli Arnason
+354-570-1900
gisli.arnason@decode.is
Joy Bessenger
+1-212-481-3891
joy.bessenger@decode.is
SOURCE deCODE genetics Inc